We are live on ! Find out more
MESO

Mesoblast

37 hedge funds and large institutions have $6.35M invested in Mesoblast in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

47% more call options, than puts

Call options by funds: $1.45M | Put options by funds: $990K

44% more capital invested

Capital invested by funds: $4.42M → $6.35M (+$1.93M)

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

12% more funds holding

Funds holding: 3337 (+4)

0.01% more ownership

Funds ownership: 0.25%0.26% (+0.01%)

Holders
37
Holders Change
+4
Holders Change %
+12.12%
% of All Funds
0.64%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
9
Reduced
7
Closed
6
Calls
$1.45M
Puts
$990K
Net Calls
+$464K
Net Calls Change
-$59K

MESO Hedge Fund Activity: Q3 2022 in Review

37 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Mesoblast (MESO) for Q3 2022, worth a combined $6.35M — up 44% from $4.42M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new MESO positions and 6 closed out — a net gain of 4 holders — while 9 added to existing stakes and 7 trimmed.

The largest buyer was Ronit Capital, opening a new position worth an estimated $453K. The largest seller was Millennium Management, exiting entirely with an estimated $95K sold.

  • 37 institutional investors held Mesoblast (MESO) as of Q3 2022, up from 33 in Q2 2022.
  • Funds reported $6.35M of Mesoblast stock for Q3 2022, up 44% quarter-over-quarter.
  • 10 funds opened new Mesoblast positions in Q3 2022 and 6 closed out, a net change of +4 holders.
  • The largest Mesoblast buyer in Q3 2022 was Ronit Capital, an estimated $453K added.
  • The largest Mesoblast seller in Q3 2022 was Millennium Management, an estimated $95K sold.

Based on aggregated 13F filings for Q3 2022.